HSS Study Finds Bone-Anchored Prosthetics Improve Mobility and Quality of Life for Leg Amputees
Leg amputees who receive bone-anchored prosthetics report high levels of satisfaction compared with those who receive conventional devices, according to new study findings published in JBJS Open Access by researchers at Hospital for Special Surgery (HSS) in New York City.
Osseointegration prostheses are a relatively new form of prosthetic technology. The approach involves surgically installing a titanium rod into a patient’s remaining bone—such as the tibia or femur in the leg—which in turn attaches to a prosthesis that allows ambulation. The technology avoids the need for traditional sockets against which limb stumps rest, an interface that produces friction that can generate significant pain and discomfort for amputees and frequently requires repair or revision.
Although osseointegration devices are available to patients in Europe and elsewhere, the U.S. Food and Drug Administration has yet to approve the technology. But the agency allows a limited number of patients to receive the implants through humanitarian exceptions.
“This is a disruptive technology to improve the life quality of amputees,” said study co-author S. Robert Rozbruch, MD, Chief of the Limb Lengthening and Complex Reconstruction Service and Director of the Limb Salvage and Amputation Reconstruction Center at HSS. “With a direct skeletal connection of the prosthetic limb, amputees report big improvements in function, comfort, balance, proprioception and even emotional connection with their limb.”
For the new study, Taylor J. Reif, MD, an orthopedic surgeon and a member of the Limb Lengthening and Complex Reconstruction Service, Dr. Rozbruch and their colleagues reviewed the medical records of 31 men and women who underwent osseointegration procedures at HSS starting in October 2017 under compassionate use exceptions. Of those, 18 had implants in the femur, or thigh bone, and 13 had implants in the tibia, the bone below the knee.
The primary outcome of the study assessed changes in the Questionnaire for Persons with a Transfemoral Amputation (QTFA), which patients complete before and after surgery. The researchers used the same questionnaire for patients with tibial amputations. They also gathered data on a range of quality-of-life measures including patient-reported functional activity, mental health, pain and self-image, as well as adverse events such as serious infections, fractures at the site of the implant and other complications of the procedure.
Researchers found that scores across all domains of the QTFA improved significantly throughout the study period. Prosthetic mobility rose from 49.7 to 81.4, while prosthetic problems fell from 46.4 to 9.1. Patients also experienced substantial gains in function with the implants, as measured by 2- and 6-minute walking tests.
Dr. Reif said the benefits of the devices extend beyond the raw numbers. “The scores going up is great, but that doesn’t necessarily capture what we’re seeing in the clinic, which is smiles on people’s faces and the expressions of gratitude for how much their lives have changed. It’s totally life-altering.”
Although some patients did experience early complications, nearly all (93%) were managed without removing the implant. Encouragingly, while some patients developed minor infections where the titanium post exits the skin (an opening called a stoma), most of these resolved with the use of oral antibiotics. Only one patient had an infection in the bone itself leading to removal.
The bond between the titanium implant and the bone is so strong that patients are able to rapidly resume physical activity. In some cases, patients can return to vigorous, weight-bearing exercise such as running within six months to one year after the procedure.
As the data showed, patients who seek osseointegration prostheses tend to be young, and most had sustained catastrophic injuries to their legs in vehicular accidents or other traumatic events. “The older population of patients have become accustomed to their sockets or using a wheelchair,” explained Dr. Reif. “But as this technology expands and more surgeons start to employ it, I think the age that these are implanted also will expand in both directions.”
He added, “No implant has a perfect track record, but when you combine the functional gains that these patients are experiencing with improvements in their quality of life, a small risk of infection or fracture is acceptable to them, as well as to the orthopedic community.”
HSS is the world’s leading academic medical center focused on musculoskeletal health. At its core is Hospital for Special Surgery, nationally ranked No. 1 in orthopedics (for the 14th consecutive year), No. 2 in rheumatology by U.S. News & World Report (2023-2024), and the best pediatric orthopedic hospital in NY, NJ and CT by U.S. News & World Report “Best Children’s Hospitals” list (2023-2024). In a survey of medical professionals in more than 20 countries by Newsweek, HSS is ranked world #1 in orthopedics for a fourth consecutive year (2023). Founded in 1863, the Hospital has the lowest readmission rates in the nation for orthopedics, and among the lowest infection and complication rates. HSS was the first in New York State to receive Magnet Recognition for Excellence in Nursing Service from the American Nurses Credentialing Center five consecutive times. An affiliate of Weill Cornell Medical College, HSS has a main campus in New York City and facilities in New Jersey, Connecticut and in the Long Island and Westchester County regions of New York State, as well as in Florida. In addition to patient care, HSS leads the field in research, innovation and education. The HSS Research Institute comprises 20 laboratories and 300 staff members focused on leading the advancement of musculoskeletal health through prevention of degeneration, tissue repair and tissue regeneration. In addition, more than 200 HSS clinical investigators are working to improve patient outcomes through better ways to prevent, diagnose, and treat orthopedic, rheumatic and musculoskeletal diseases. The HSS Innovation Institute works to realize the potential of new drugs, therapeutics and devices. The HSS Education Institute is a trusted leader in advancing musculoskeletal knowledge and research for physicians, nurses, allied health professionals, academic trainees, and consumers in more than 165 countries. The institution is collaborating with medical centers and other organizations to advance the quality and value of musculoskeletal care and to make world-class HSS care more widely accessible nationally and internationally. www.hss.edu.